Melatonin 관련 수면 관련 인지 장애
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.Well-established for sleep optimization, melatonin may support cognitive function indirectly by promoting glymphatic clearance of beta-amyloid and other metabolic waste during sleep.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Dmelatonin\u0026condition\u003Dsleep\u002Dcognitive';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
Well-established for sleep optimization, melatonin may support cognitive function indirectly by promoting glymphatic clearance of beta-amyloid and other metabolic waste during sleep.
Key Study Findings
review
Pediatric Insomnia.
Dose: Melatonin (various doses), CBT-I (behavioral), pharmacologic options (z-drugs, other)
vs: Placebo
효과: CBT-I most effective treatment; melatonin beneficial in children with ASD or ADHD; limited evidence
None
Other
Banxia Shumi Decoction Improves Sleep and Neural Function in Insomnia Male Rats via BDNF/TrkB/CREB-Dependent Melatonin …
Dose: None
vs: PCPA-induced insomnia model control
Outcome: Sleep quality and cognitive function in rat model
효과: None
None
대상 집단: PCPA-induced insomnia male rats
Randomized Controlled Trial
n=322
5 weeks
Double-blind
Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, …
Dose: 20 mg or 50 mg tasimelteon daily
vs: Placebo
Outcome: Latency to persistent sleep (PSG)
효과: -44.9 min (20mg) / -46.3 min (50mg) vs -28.2 (placebo)
<0.001
대상 집단: Patients with primary insomnia (sleep onset difficulty)
Review
Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment.
Dose: None
vs: None
Outcome: ISWRD symptom management
효과: None
None
대상 집단: Patients with irregular sleep-wake rhythm disorder
review
Insomnia in older adults: A review of treatment options.
Dose: various
vs: Placebo
효과: None
None
Review
Commonly encountered symptoms and their management in patients with cirrhosis.
Dose: None
vs: None
Outcome: Pain outcomes
효과: None
None
대상 집단: Insomnia patients
Key Statistics
15
연구
2000
참여자
↑
Positive
C
등급
Referenced Papers
Pediatric Insomnia.
Review
Pediatrics in review
2026
Cleveland Clinic journal …
2025
12 인용
Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment.
Review
Handbook of clinical …
2025
4 인용
PloS one
2025
1 인용
Neurochemical research
2025
Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis.
Meta-Analysis
JNCI cancer spectrum
2024
24 인용
Journal of neurology
2024
21 인용
Antioxidants (Basel, Switzerland)
2024
17 인용
Current opinion in …
2024
12 인용
Frontiers in medicine
2024
4 인용
La Revue du …
2024
Complementary and alternative treatments for insomnia disorder: a systematic umbrella review.
Systematic Review
Journal of sleep …
2023
12 인용
Journal of pineal …
2023
7 인용
Frontiers in neuroscience
2023
5 인용
Current drug safety
2023
2 인용
BMJ open
2022
3 인용
NPJ Parkinson's disease
2022
Progress in neuro-psychopharmacology …
2021
68 인용
Frontiers in neurology
2021
16 인용
A Systematic Review of the Efficacy and Safety of Over-the-Counter Medications Used in Older People for the Treatment of Primary …
Systematic Review
The Senior care …
2021
12 인용
Neural regeneration research
2021
6 인용
Climacteric : the …
2020
97 인용
Neurotherapeutics : the …
2020
80 인용
Current treatment options …
2020
29 인용
Human brain mapping
2020
15 인용
Dermatitis : contact, …
2019
7 인용
Journal of sleep …
2017
1691 인용
Neurological research
2017
331 인용
Nutrients
2017
301 인용
Current treatment options …
2017
56 인용
Journal of pineal …
2017
45 인용
Clinical therapeutics
2016
328 인용
Pediatric Insomnia.
Review
Chest
2016
109 인용
European heart journal. …
2016
77 인용
Diabetes, obesity & …
2015
132 인용
Alcohol (Fayetteville, N.Y.)
2015
122 인용
Menopause (New York, …
2015
73 인용
Chest
2013
53 인용
PloS one
2012
14 인용
Pharmacological reports : …
2011
99 인용
Progress in neuro-psychopharmacology …
2011
71 인용
Der Nervenarzt
2009
6 인용
Pharmacotherapy
2007
117 인용
Tidsskrift for den …
2006
Brain research. Molecular …
2005
160 인용
Reviews of reproduction
1998
381 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 0.5-5 mg/day
- sleepcognitivesupport:
- 0.5-3 mg 30-60 min before bed
상한량: 10 mg/day (higher doses not more effective)
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| Melatonin (various doses), CBT-I (behavioral), pharmacologic options (z-drugs, other) | -- | Positive | -- |
| None | -- | Positive | -- |
| 20 mg or 50 mg tasimelteon daily | 5 weeks | Positive | 322 |
| None | -- | Mixed | -- |
| various | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Positive | 6528 |
| Z-drugs, melatonin, orexin antagonists | -- | Positive | -- |
권장 복용 시간: 30-60 minutes before bedtime
Safety & Side Effects
보고된 부작용
- ⚠ Daytime drowsiness
- ⚠ Headache
- ⚠ Dizziness
- ⚠ Nausea
- ⚠ Vivid dreams
알려진 상호작용
- ● Sedative medications (additive drowsiness)
- ● Blood thinners (may increase bleeding risk)
- ● Diabetes medications (may affect blood sugar)
- ● Immunosuppressants (may stimulate immune function)
- ● Oral contraceptives (may increase melatonin levels)
일일 최대 섭취 허용량: 10 mg/day (higher doses not more effective)
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Melatonin help with 수면 관련 인지 장애?
Based on 15 studies with 2,000 participants, there is limited but promising evidence that Melatonin may support 수면 관련 인지 장애 management. Our evidence grade is C (Some Evidence).
How much Melatonin should I take for 수면 관련 인지 장애?
Studies have used various dosages. A commonly studied range is 0.5-5 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Melatonin?
Reported side effects may include Daytime drowsiness, Headache, Dizziness, Nausea. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Melatonin and 수면 관련 인지 장애?
We rate the evidence as Grade C (Some Evidence). This rating is based on 15 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 수면 관련 인지 장애
References
- [1] Rayan Kteish et al.. Pediatr Rev. 2026. Pediatric Insomnia. doi:10.1542/pir.2024-006687 PubMed
- [2] Roberto León-Barriera et al.. Cleve Clin J Med. 2025. Insomnia in older adults: A review of treatment options. doi:10.3949/ccjm.92a.24073 PubMed
- [3] Aleksandar Videnovic et al.. Handb Clin Neurol. 2025. Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment. doi:10.1016/B978-0-323-90918-1.00006-X PubMed
- [4] Naoise C Synnott et al.. PLoS One. 2025. Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. doi:10.1371/journal.pone.0332366 PubMed
- [5] Baojun Guo et al.. Neurochem Res. 2025. Banxia Shumi Decoction Improves Sleep and Neural Function in Insomnia Male Rats via BDNF/TrkB/CREB-Dependent Melatonin Signaling Activation. doi:10.1007/s11064-025-04556-y PubMed
- [6] Eva Rames Nissen et al.. JNCI Cancer Spectr. 2024. Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis. doi:10.1093/jncics/pkae041 PubMed
- [7] Laura Palagini et al.. J Neurol. 2024. Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group. doi:10.1007/s00415-023-12112-3 PubMed
- [8] Kazim Sahin et al.. Antioxidants (Basel). 2024. Impact of a Novel Valerian Extract on Sleep Quality, Relaxation, and GABA/Serotonin Receptor Activity in a Murine Model. doi:10.3390/antiox13060657 PubMed
- [9] Bhavya Narala et al.. Curr Opin Pediatr. 2024. Delayed sleep wake phase disorder in adolescents: an updated review. doi:10.1097/MOP.0000000000001322 PubMed
- [10] Cyriac Abby Philips. Front Med (Lausanne). 2024. Commonly encountered symptoms and their management in patients with cirrhosis. doi:10.3389/fmed.2024.1442525 PubMed
- [11] Marie-Françoise Vecchierini et al.. Rev Prat. 2024. [Pharmacotherapies for insomnia]. PubMed
- [12] Johanna Ell et al.. J Sleep Res. 2023. Complementary and alternative treatments for insomnia disorder: a systematic umbrella review. doi:10.1111/jsr.13979 PubMed
- [13] Hui Yang et al.. J Pineal Res. 2023. RP58 knockdown contributes to hypoxia-ischemia-induced pineal dysfunction and circadian rhythm disruption in neonatal rats. doi:10.1111/jpi.12885 PubMed
- [14] Nijee S Luthra et al.. Front Neurosci. 2023. Targeting neuroendocrine abnormalities in Parkinson's disease with exercise. doi:10.3389/fnins.2023.1228444 PubMed
- [15] Mrinalini Ravikumar et al.. Curr Drug Saf. 2023. The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease. doi:10.2174/1574886317666220517125644 PubMed
- [16] Yulin Sun et al.. BMJ Open. 2022. Melatonin supplementation for the treatment of infantile spasms: protocol for a randomised placebo-controlled triple-blind trial. doi:10.1136/bmjopen-2021-057970 PubMed
- [17] Jingwen Li et al.. NPJ Parkinsons Dis. 2022. Melatonin ameliorates Parkinson's disease via regulating microglia polarization in a RORα-dependent pathway. doi:10.1038/s41531-022-00352-5 PubMed
- [18] Pierre A Geoffroy et al.. Prog Neuropsychopharmacol Biol Psychiatry. 2021. Biological rhythms and chronotherapeutics in depression. doi:10.1016/j.pnpbp.2020.110158 PubMed
- [19] Xiaoli Wu et al.. Front Neurol. 2021. Circadian Rhythm Disorders and Corresponding Functional Brain Abnormalities in Young Female Nurses: A Preliminary Study. doi:10.3389/fneur.2021.664610 PubMed
- [20] Sandrah-Ann M Almond et al.. Sr Care Pharm. 2021. A Systematic Review of the Efficacy and Safety of Over-the-Counter Medications Used in Older People for the Treatment of Primary … doi:10.4140/TCP.n.2021.83 PubMed
- [21] Ning Sha et al.. Neural Regen Res. 2021. The role of pineal microRNA-325 in regulating circadian rhythms after neonatal hypoxic-ischemic brain damage. doi:10.4103/1673-5374.308101 PubMed
- [22] P Proserpio et al.. Climacteric. 2020. Insomnia and menopause: a narrative review on mechanisms and treatments. doi:10.1080/13697137.2020.1799973 PubMed
- [23] José Rafael P Zuzuárregui et al.. Neurotherapeutics. 2020. Sleep Issues in Parkinson's Disease and Their Management. doi:10.1007/s13311-020-00938-y PubMed
- [24] Luigi Ferini-Strambi et al.. Curr Treat Options Neurol. 2020. Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease. doi:10.1007/s11940-020-0612-z PubMed
- [25] Feifei Zhang et al.. Hum Brain Mapp. 2020. The effect of jet lag on the human brain: A neuroimaging study. doi:10.1002/hbm.24945 PubMed
- [26] Aleksi J Hendricks et al.. Dermatitis. 2019. Clinical Pearls on Sleep Management in Atopic Dermatitis. doi:10.1097/DER.0000000000000523 PubMed
- [27] Dieter Riemann et al.. J Sleep Res. 2017. European guideline for the diagnosis and treatment of insomnia. doi:10.1111/jsr.12594 PubMed
- [28] Zizhen Xie et al.. Neurol Res. 2017. A review of sleep disorders and melatonin. doi:10.1080/01616412.2017.1315864 PubMed
- [29] Xiao Meng et al.. Nutrients. 2017. Dietary Sources and Bioactivities of Melatonin. doi:10.3390/nu9040367 PubMed
- [30] Amy W Amara et al.. Curr Treat Options Neurol. 2017. Treatment of Sleep Dysfunction in Parkinson's Disease. doi:10.1007/s11940-017-0461-6 PubMed
- [31] Deetje Iggena et al.. J Pineal Res. 2017. Melatonin restores hippocampal neural precursor cell proliferation and prevents cognitive deficits induced by jet lag simulation in adult mice. doi:10.1111/jpi.12397 PubMed
- [32] Jennifer L Schroeck et al.. Clin Ther. 2016. Review of Safety and Efficacy of Sleep Medicines in Older Adults. doi:10.1016/j.clinthera.2016.09.010 PubMed
- [33] Kelly M Brown et al.. Chest. 2016. Pediatric Insomnia. doi:10.1378/chest.15-0605 PubMed
- [34] Lionel H Opie et al.. Eur Heart J Cardiovasc Pharmacother. 2016. Melatonin has multiorgan effects. doi:10.1093/ehjcvp/pvv037 PubMed
- [35] E Challet. Diabetes Obes Metab. 2015. Keeping circadian time with hormones. doi:10.1111/dom.12516 PubMed
- [36] Kirk J Brower. Alcohol. 2015. Assessment and treatment of insomnia in adult patients with alcohol use disorders. doi:10.1016/j.alcohol.2014.12.003 PubMed
- [37] Hrayr Attarian et al.. Menopause. 2015. Treatment of chronic insomnia disorder in menopause: evaluation of literature. doi:10.1097/GME.0000000000000348 PubMed
- [38] Jeremy A Weingarten et al.. Chest. 2013. Air travel: effects of sleep deprivation and jet lag. doi:10.1378/chest.12-2963 PubMed
- [39] Irina V Zhdanova et al.. PLoS One. 2012. Familial circadian rhythm disorder in the diurnal primate, Macaca mulatta. doi:10.1371/journal.pone.0033327 PubMed
- [40] Monika Banach et al.. Pharmacol Rep. 2011. Melatonin in experimental seizures and epilepsy. doi:10.1016/s1734-1140(11)70393-0 PubMed
- [41] Venkatramanujan Srinivasan et al.. Prog Neuropsychopharmacol Biol Psychiatry. 2011. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? doi:10.1016/j.pnpbp.2011.03.013 PubMed
- [42] Dieter Riemann et al.. Nervenarzt. 2009. [Insomnias. II. Pharmacological and psychotherapeutic treatment options]. doi:10.1007/s00115-009-2746-9 PubMed
- [43] Anna K Morin et al.. Pharmacotherapy. 2007. Therapeutic options for sleep-maintenance and sleep-onset insomnia. doi:10.1592/phco.27.1.89 PubMed
- [44] Anders Johnsson et al.. Tidsskr Nor Laegeforen. 2006. [Rhythms, depressions and light]. PubMed
- [45] Birgit M Dietz et al.. Brain Res Mol Brain Res. 2005. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. doi:10.1016/j.molbrainres.2005.04.009 PubMed
- [46] J Arendt. Rev Reprod. 1998. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. doi:10.1530/ror.0.0030013 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.